"At Carteret Medical Group, our primary care services are cost-effective and close to home. That means there is no reason to travel to receive the highest-quality medical treatment. We seek to establish long-term relationships with our patients by providing reliable, cost-effective treatment, even if you are being circulated to various medical specialists."

During the past decade, Carteret Medical Group conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 7 clinical trials were completed, i.e. on average, 58.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 7 clinical trials were completed. i.e. 116.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Carteret Medical Group" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "DexCom, Inc." with 2 trials sponsored, "Brigham and Women's Hospital" with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "Idorsia Pharmaceuticals Ltd." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Carteret Medical Group" #1 collaborator was "AbCellera Biologics Inc." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Jaeb Center for Health Research" with 1 trials as a collaborator, "Janssen Biotech, Inc." with 1 trials as a collaborator and "Mylan GmbH" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Carteret Medical Group" are "Alzheimer Disease" (2 trials), "Diabetic Kidney Disease" (2 trials), "Alzheimer's Disease" (1 trials), "COVID-19" (1 trials) and "Cardiovascular Disease" (1 trials). Many other conditions were trialed in "Carteret Medical Group" in a lesser frequency.

Most popular intervention types in "Carteret Medical Group" are "Drug" (9 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Donanemab" (2 trials), "Aprocitentan 12.5 mg" (1 trials), "Aprocitentan 25 mg" (1 trials) and "Bamlanivimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Carteret Medical Group" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Carteret Medical Group". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Carteret Medical Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Carteret Medical Group, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".